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Abstract
Background The beneficial effects of dietary restriction
of proteins in chronic kidney disease are widely recog-
nized; however, poor compliance to prescribed low-protein
diets (LPD) may limit their effectiveness. To help patients
to adhere to the dietary prescriptions, interventions as
education programmes and dietary counselling are critical,
but it is also important to develop simple and attractive
approaches to the LPD, especially when dietitians are not
available. Therefore, we elaborated a simplified and easy to
manage dietary approach consisting of 6 tips (6-tip diet,
6-TD) which could replace the standard, non-individual-
ized LPD in Nephrology Units where dietary counselling is
not available; hence, our working hypothesis was to eval-
uate the effects of such diet vs a standard moderately
protein-restricted diet on metabolic parameters and
patients’ adherence.
Methods In this randomized trial, 57 CKD patients stage
3b-5 were randomly assigned (1:1) to receive the 6-TD
(Group 6-TD) or a LPD containing 0.8 g/kg/day of proteins
(Group LPD) for 6 months. The primary endpoint was to
evaluate the effects of the two different diets on the main
‘‘metabolic’’ parameters and on patients’ adherence (reg-
istration number NCT01865526).
Results Both dietary regimens were associated with a
progressive reduction in protein intake and urinary urea
excretion compared to baseline, although the decrease was
more pronounced in Group 6-TD. Effects on serum levels of
urea nitrogen and urinary phosphate excretion were greater
in Group 6-TD. Plasma levels of phosphate, bicarbonate and
PTH, and urinary NaCl excretion remained stable in both
groups throughout the study. 44 % of LPD patients were
adherent to the dietary prescription vs 70 % of Group 6-TD.
Conclusions A simplified diet, consisting of 6 clear
points easily managed by CKD patients, produced benefi-
cial effects either on the metabolic profile of renal disease
and on patients’ adherence to the dietary plan, when
compared to a standard LPD.
Keywords Adherence  Chronic kidney disease 
Low-protein diet  Protein intake
Introduction
Dietary restriction of proteins and sodium is a cornerstone
in the treatment of chronic kidney disease (CKD) for its
ability to reduce the work load of surviving nephrons and
to lessen the signs and symptoms of uraemia, as well as for
its positive metabolic impact. Moreover, the reduction in
dietary sodium intake contributes to reduce hypertension in
advanced CKD [1–7]. Although the dietary treatment does
not reduce the decline in glomerular filtration rate (GFR), it
delays renal death sparing patients with CKD from dialysis
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by 1–2 years [8–10] and may also be considered a cost-
effective therapy [11].
Dietary adjustments in subjects with CKD, however, are
complex and imply a major change in lifestyle. Further-
more, low-protein diets (LPDs) are considered tedious,
unpalatable and expensive, and are therefore often associ-
ated with a low patients’ compliance in the long term [12,
13]. Since poor dietary adherence nullifies the advantages
of such treatment, a better compliance to this therapeutic
approach is a critical issue to reach and represents a leading
challenge to healthcare professionals [14].
A key process to obtain adequate adherence to LPDs is
to provide individualized dietary programmes and specific
periodic counselling by skilled renal dietitians, possibly
joined with intensive educational programmes [15]. These
strategies, however, need dedicated personnel and are time
and money consuming [16].
In Nephrology Units devoid of such possibilities [16],
the usual practice is to prescribe to CKD patients standard,
non-individualized LPDs (with no counselling), or even to
maintain their usual diet, thus renouncing to the benefits of
LPDs. To overcome these difficulties, we have elaborated
an easy dietary plan, consisting of 6 written suggestions,
which could replace the use of the standard LPDs (6-tip
diet, 6-TD, Table 1). These ‘‘tips’’ are based on the same
principles that regulate usual LPDs but are more easily
understood and memorized by patients.
Therefore, the aim of the present study was to evaluate,
in patients with CKD, the ability of the 6-TD to reduce
protein, phosphate and sodium intake, and the degree of
compliance to this dietary plan in comparison with stan-
dard LPDs.
Subjects and methods
Patients
This prospective, randomized study was carried out in the
CKD Unit of the University Federico II of Naples, Italy,
where 61 consecutive patients (stage 3b-5 CKD), admitted
in our Unit for a clinical assessment of chronic renal fail-
ure, were screened from March 2010 to December 2012.
Inclusion criteria for the study were age[18 years, esti-
mated GFR (eGFR) B45 ml/min/1.73 m2, and dietary
protein intake 0.7–0.9 g/kg/day stable throughout their
hospital stay. Exclusion criteria included inability to per-
form correct 24 h urine collections, malignancies, treat-
ment with immunosuppressive drugs, pregnancy,
congestive heart failure (NYHA class III–V), or proteinuria
[3.5 g/24 h.
Withdrawal from the study was considered in case of
malnutrition (loss of body weight[5 % in 1 month or BMI
\20 kg/m2 with serum albumin levels\3.2 g/dl), need to
start dialysis (eGFR B6 ml/min, K? [6.0 mEq/L,
intractable hypertension), development of other serious
clinical conditions, or death.
The study was approved by the Local Ethics Committee
and was in adherence with the Declaration of Helsinki.
Informed written consent was obtained from each patient.
Study design and procedures
Accordingly to our inclusion/exclusion criteria, 57 patients
were enrolled in the study and were randomly assigned
(1:1) to receive the 6-TD or a standard LPD; the random-
ization list was generated by means of a computer and kept
concealed with the use of numbered, sealed envelopes
opened in sequence by administrative staff personnel not
involved in patients care.
The first arm received, by the nephrologist, a list of six
items indicating how to modify their dietary habits at time
of discharge (Group 6-TD; Table 1); all the items were
thoroughly explained and discussed with the patients. In
particular, the patients and their partners were advised to
eat portions of the single foods similar as those of the
hospital (defined as ‘‘usual’’ in the diet scheme); moreover,
all the patients were encouraged to eat fruit and vegeta-
bles during the 3 daily meals. No food list nor specific
frequencies for any food were suggested.
Patients of the second arm received a written, standard
diet containing 0.8 g of proteins/kg of desirable body
weight/day, which contained at least 30 kcal/kg/day (25 in
overweight patients), 3 and 6 g NaCl/day, and included
hypoproteic noodle and bread (Group LPD). Such a diet,
not customized to patients’ dietary habits, was carefully
explained to the patients by the nephrologist and included a
list of allowed foods.
No further nutritional counselling was provided there-
after in both groups.
All the patients were followed up for 6 months, with
three further clinical, nutritional, and laboratory controls
after one (T1), three (T3), and 6 months (T6), beyond
Table 1 The six-tip diet
1. Do not add salt at table and for cooking
2. Food to avoid: any kind of salami, sausages, cheese and dairy
products or canned food
3. Replace noodle or bread with special hypoproteic food
4. The second course (meat, fish and eggs) are allowed once a day in
the usual quantity
5. 4–5 servings/day of fruits or vegetables are suggested
6. Once or twice a week the main course may be of ‘‘normal’’
noodle with legumes instead of the second course, with fruit
and vegetables
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baseline (T0). At each time point, blood was withdrawn to
determine the main laboratory data; urinary urea nitrogen
(UUN), sodium, potassium, phosphate, and protein excre-
tion were also determined in samples from 24 h collec-
tions. Standard laboratory procedures were used for blood
and urine measurements.
During their hospital stay, patients were prescribed
pharmacological therapies in order to achieve the thera-
peutic targets suggested by K/DOQI guidelines for stage
3b-5. All the therapies were maintained throughout the
follow-up period.
Renal function was expressed as eGFR, calculated by
MDRD equation [17]. Dietary protein intake was estimated
by daily UUN excretion and non-ureic nitrogen faecal or
urinary loss or according to Maroni formula [18]. Changes
in estimated protein intake defined adherence to prescribed
diet over time. As in our previous study [19], the adherence
to LPD was defined by a constant protein intake between
0.7 and 0.9 g/kg BW/day throughout the study; any patient
out of this range during the follow-up period was consid-
ered ‘‘non-adherent.’’ The same interval was arbitrarily
considered as synonymous of compliance also in patients
of Group 6-TD. The adherence to caloric prescription was
indirectly verified by body weight variation.
Endpoints
The primary efficacy end point of the study was to compare
the effects of the two different diets, (6-TD and LPD) on
protein intake, UUN excretion, serum urea nitrogen, uri-
nary phosphate excretion, and serum phosphate concen-
tration during a follow-up period of 6 months. As
secondary endpoints, we also evaluated patients’ adherence
to the prescribed diet, and the effects of both diets on
several additional metabolic (sodium, potassium, bicar-
bonate, parathyroid hormone) and nutritional parameters
(BMI, serum albumin).
Statistical analysis
The primary outcome measure with respect to efficacy was
the mean decrease in protein intake from baseline to
6 months which was compared between two groups.
Assuming a clinically significant difference of 0.15 g/
kg/day in mean decrease between groups with a standard
deviation (SD) of the differences equal to 0.2 g/kg/day, a
power of 80 %, and 2-sided significance level of 5 %, a
minimal sample size of 58 subjects (29 for each group) was
calculated.
Analysis of change from baseline for the primary end-
points was performed using separate ANCOVA models
with dietary regimen as a between group factor, time (1, 3,
6 months) as within factor and baseline values of
dependent variable as covariates. Results from the
ANCOVA models are expressed as estimated marginal
means with 95 % CI both for the mean change from
baseline within each dietary regimen as well as for the
difference in mean change from baseline between groups.
For each group and for each time point, the change from
baseline was deemed significant, at a significance level of
0.05, if the estimated 95 % CI do not cross the zero values
with no adjustment for multiplicity. The effect of dietetic
therapy on patients’ compliance, defined by a constant
protein intake between 0.7 and 0.9 g/kg BW, measured at
1, 3, and 6 months, was evaluated by Chi-Square test.
Statistical analyses were performed with the statistical
computing environment R (version 3.0.1; R Foundation for
Statistical Computing, Vienna, Austria).
Results
Baseline data
As shown in Fig. 1, 57 of 61 patients assessed for eligi-
bility were randomized to the two different diets: 28 to
6-TD (Group 6-TD) and 29 to LPD (Group LPD). More-
over, three patients (2 in Group LPD, 1 in Group 6-TD)
developed a proteinuria[3.5 g/24 h during the follow-up
and were excluded from the study; accordingly, the sta-
tistical analysis was performed on 54 patients (n = 27 in
each group), who completed the study (Fig. 1).
The characteristics of these patients are summarized in
Table 2. At baseline, the two groups were comparable for
age, sex, body weight, eGFR (and distribution of CKD
stages), and concomitant treatments. Moreover, blood
pressure did not differ among patients of both groups (data
not shown). Baseline laboratory data are reported in
Table 3; no difference was detected between the two
groups.
It is noteworthy that in both groups, the main laboratory
data were in the desired range, mostly considering the
severely reduced eGFR. Both groups, however, started
from values of daily protein intake slightly higher than
expected, considering that all the patients were prescribed a
moderately protein-restricted diet during their hospital stay
(0.7–0.8 g/kg/day of proteins and 6 g/day of NaCl).
Follow-up data
The complete data (T0–T6) of main blood and clinical
parameters of both groups of patients are reported in
Table 4.
Both dietary regimens were associated with a progres-
sive and significant reduction in UUN excretion compared
to baseline since the first month of study (T1), although to a
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different extent (Table 5). Starting from the third month of
diet (T3), the differences in UUN excretion in the two
groups under study became statistically significant (mean
difference between groups: -1.8 g/day, 95 % CI -3.0 to
-0.6, p = 0.005), and such difference persisted at T6
(mean difference between groups: -1.5 g/day, 95 % CI
-2.6 to -0.4, p = 0.008) (Table 5; Fig. 2a).
Daily phosphate excretion showed a divergent pattern in
the two groups (Table 5; Fig. 2b); in fact, patients of the
Group 6-TD showed a decrease in phosphate excretion
compared to baseline, statistically significant since the first
month of study, which progressively decreased until T6. In
the Group LPD, conversely, daily phosphate excretion
remained stable throughout the study. Starting from T3, the
differences in phosphate excretion between the groups
under study became statistically significant (mean differ-
ence between groups: -102.9 mg/day, 95 % CI -197.1 to
-8.7, p = 0.033), and such difference persisted at T6
(mean difference between groups: -137.6 mg/day, 95 %
CI -231.0 to -44.2, p = 0.005) (Table 5; Fig. 2b).
This discrepancy, however, did not influence serum
phosphate concentrations that remained quite stable and in
the normal range throughout the study in both groups
(Tables 4, 5).
The decreased urinary excretion of urea and phosphate
mirrored the significant reduction in protein intake in both
groups during the follow-up period, observed since the
third month of study (Fig. 2c; Tables 4, 5). However,
starting from T3, the treatment effect became more pro-
nounced in the Group 6-TD (-0.13 g/kg/day, 95 % CI
-0.24 to -0.02, p = 0.022) and such difference persisted
at T6 (difference between groups: -0.11 g/kg/day, 95 %
CI -0.21 to -0.01, p = 0.040).
In partial agreement with such data, a significant dif-
ference was also detected in serum urea nitrogen (SUN)
levels, that remained stable in Group LPD, but progres-
sively decreased in Group 6-TD (difference between
groups: -19.6 mg/day, 95 % CI -34.8 to -4.4,
p = 0.012) (Table 5; Fig. 2d).
Conversely, and quite unexpectedly, the reduction in
nutrients intake was not associated with a concomitant
decline in urinary sodium chloride excretion, which was
substantially high at baseline (Table 3) and was not mod-
ified during the follow-up (Table 5).
Only marginal variations were detected in bicarbonate
levels in both groups with respect to baseline, with no
significant change between the groups throughout the
6-month follow-up period (Fig. 2e; Tables 4, 5).
Screened
n = 61
Randomized
n = 57
Screened but not randomized (n = 4)
Not meeng inclusion criteria        2
Refused to participate                     2
Group 6-TD
n = 28
Group LPD
n = 29
Lost to follow-up           (n=1)
Proteinuria >3.5 g/24 h     1
Completed the study
n = 27
Lost to follow-up           (n=2)
Proteinuria >3.5 g/24 h     2
Completed the study
n = 27
Fig. 1 Patient disposition
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Table 2 Demographic
characteristics of the two groups
under study at baseline
Group 6-TD (n = 27) Group LPD (n = 27)
Gender (% female) 48 48
Age (years) 58.8 ± 12.06 56.1 ± 12.06
BMI (kg/m2) 25.9 ± 6.99 27.15 ± 4.05
eGFR (mL/min/1.73 m2) 21.2 ± 7.4 20.9 ± 8.3
CKD stage (%)
Stage 3b (30–45 mL/min/1.73 m2) 11 11
Stage 4 (15–30 mL/min/1.73 m2) 59 59
Stage 5 (\15 mL/min/1.73 m2) 30 30
Renal disease (%)
GN 29 26
DM 22 25
ADPKD 20 18
Urological causes 3 5
Other/unknown 26 24
Drug treatments (%)
Antihypertensive drugs 90 88
Phosphate binders 36 38
Lipid lowering agents 41 39
Bicarbonate supplements 78 74
Diuretics 9 10
Vitamin D analogues 5 6
Iron supplements 34 33
ESA 28 30
Table 3 Main laboratory data
of the patients of the two diet
groups at baseline
Group 6-TD (n = 27) Group LPD (n= 27)
Serum parameters
Serum creatinine (mg/dL) 3.3 ± 1.32 3.3 ± 1.28
Serum urea (mg/dL) 105 ± 29 113 ± 32
Serum potassium (mEq/L) 5.06 ± 0.47 5.18 ± 0.66
Serum phosphate (mg/dL) 3.97 ± 0.7 3.98 ± 0.82
Serum calcium (mg/dL) 9.5 ± 0.5 9.4 ± 0.3
Serum bicarbonate (mEq/L) 23.4 ± 2.4 24.1 ± 3.5
Serum albumin (g/dL) 4.47 ± 0.23 4.42 ± 0.29
Intact-PTH (pg/mL) 155 ± 138 136 ± 84
Total cholesterol (mg/dL) 179 ± 36 187 ± 34
Triglycerides (mg/dL) 138 ± 85 125 ± 49
Hb (g/dL) 11.4 ± 1.2 11.2 ± 1.1
Transferrin (lg/dL) 305.4 ± 76.3 298.7 ± 95.4
CRP (mg/dL) 0.9 ± 0.3 1.1 ± 0.5
Urinary parameters
Proteinuria (g/day) 1.6 ± 1.7 1.5 ± 1.4
UUN excretion (g/day) 9.2 ± 3.3 9.5 ± 2.3
Phosphate excretion (mg/day) 619.3 ± 158.8 606.9 ± 214.6
NaCl excretion (mEq/day) 159.3 ± 53.5 174.4 ± 58.3
Protein intake (g/kg/day) 0.94 ± 0.21 0.96 ± 0.2
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No modification was observed throughout the study
period in the other laboratory data, including serum albu-
min (Table 4), haemoglobin, sodium, potassium, PTH and
urinary protein excretion, and BP in both groups (data not
shown).
Last, although the progression of renal failure was not
an outcome of the trial, patients of Group LPD experienced
a slight but significant decrease of eGFR starting from the
third month of follow-up, while renal function remained
remarkably stable in Group 6-TD (Fig. 2f; Table 4).
According to the protocol, patients were maintained at
the same pharmacological therapies throughout the follow-
up period.
Compliance data
Following our arbitrary definition of ‘‘dietary adherence’’,
i.e., daily protein intake never exceeding the range
0.7–0.9 g/kg/day in each time point of the study, 19
patients (70 %) of Group 6-TD were considered adherent
to our prescription, compared to only 11 patients of Group
LPD (44 %), although such difference did not achieve
statistical significance. No patient had a protein intake
below 0.7 g/kg/day throughout the follow-up period.
Conversely, since BW remained stable in both groups
during the entire study period, the caloric intake was
considered acceptable in both in LPD and 6-TD patients.
Discussion
The key finding of our randomized trial is that a simplified
diet, consisting of 6 clear points easily managed by patients
with CKD, produced beneficial effects either on the
metabolic profile of renal disease and on patients’ adher-
ence to the dietary plan, when compared to a moderately
low-protein diet (0.8 g/kg/day).
Although the beneficial metabolic effects of LPDs are
widely recognized, diet efficacy is hampered by the low
patients’ adherence [21]. Clinical trials generally employ
extensive dietary counselling and close clinical monitoring
in selected patients to enhance dietary compliance; nev-
ertheless, adherence to LPDs continues to be poor [22–25]
and is even worse in current medical practice, if patients
benefit of less intensive care either in terms of education
and of periodic dietary counselling. Therefore, it seems
crucial to develop easier and more flexible approaches to
LPDs able to join metabolic efficacy and better acceptance
[20], as also recently suggested by Piccoli et al., who
allowed 1–3 unrestricted meals/week and a tailored control
policy in patients prescribed 0.6 g/kg/day, reaching an
average protein intake of 0.7 g/kg/day [26].
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These considerations induced us to develop a new, simpli-
fied and easy to manage dietary plan to improve patients’
acceptance and adherence when dietary counselling is not
available; hence, our working hypothesis was to evaluate the
effects of such diet compared to a standard,moderately protein-
restricteddiet onmetabolic parameters andpatients’ adherence.
Although KDOQI guidelines still recommend diets
containing 0.6 g/kg/day of proteins, we chose to prescribe
a 0.8 g/kg/day diet, a low-normal protein diet, since there
is evidence in the literature that such intake still positively
influences metabolic parameters and may be reached in the
majority of CKD patients [20].
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Fig. 2 Mean changes in UUN excretion (a), urinary phosphate
excretion (b), protein intake (c), serum urea nitrogen (d), bicarbonate
(e), and GFR (f) for Group 6-TD (circles) and Group LPD (triangles).
Error bars represent 95 % CIs as estimated by ANCOVA models for
repeated measures with baseline values as covariates. UUN urinary
urea nitrogen, GFR glomerular filtration rate
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Our data demonstrate that the 6-TD was associated with
a better metabolic pattern compared to standard LPDs, as
primary efficacy end point. In fact, despite both diets were
associated with a significant decrease in protein intake
compared to their respective baseline intake during the
6-month follow-up, such reduction was more pronounced
in patients with 6-TD. Accordingly, even urinary urea
excretion and serum urea nitrogen decreased significantly
more with 6-TD than with LPD.
Also phosphate excretion decreased significantly more
in 6-TD patients than in Group LPD; this difference,
however, did not influence phosphate plasma levels that
remained similar and in the normal range in both groups
throughout the study. It is possible that LPD patients
ingested a greater amount of ‘‘hidden phosphorus’’ in
prepared foods, which may significantly contribute to the
phosphorus burden in CKD patients [25]; the use of
phosphate binders probably allowed plasma phosphate
concentration to remain in the normal range.
In both groups, the intake of NaCl averaged 10 g/day, far
exceeding that recommended at baseline (point #1 of our
6-TD), and remained quite stable throughout the study. This
was not surprising, since adherence to salt restriction is likely
the most difficult to achieve in CKD patients, and even the
use of very low-protein diets (VLPDs) in adherent patients
allows just a small reduction in salt intake [7]. In our setting,
moreover, the peculiar dietary habits of Southern Italy,
characterized by high salt ingestion and the increased intake
of sodium bicarbonate in most patients of both Group LPD
and 6-TD (74 and 78 %, respectively), further contributed to
this result. These data suggest that a greater effort should be
made to strengthen the concept of limiting salt intake with
either diet, of minimizing the use of specific foods and also of
avoiding particular sauces or preserved food.
As second end point of the study, we also evaluated
patients’ adherence to both diets, a critical issue in CKD
patients. We have previously reported that patients’ com-
pliance to a diet containing 0.6 g/kg/day of protein did not
exceed 20 % during the 1 year follow-up, despite dietary
counselling [13]; the better compliance observed in MDRD
study [23] using a similar dietary regimen, (35–46 % in
study A and B, respectively) merely reflected the wider
‘adherence range’ for protein intake (±30 %), far higher
than ours (±12 %). Better results in terms of adherence
were obviously obtained with higher intakes of nutrients
(and proteins): 53 % of patients assigned to a 0.8 g/kg/day
diet were able to follow our prescription during a 18-month
follow-up, and such percentage raised to 76 % including
also patients prescribed a very strict protein intake (0.55 g/
kg/day) that did not exceed 0.8 g/kg/day [20]. Unfortu-
nately, the dietary adherence in Group LPD of the present
study was very low: only 44 % of patients, in fact,
remained in the desired range of protein intake, much less
than expected on the basis of our previous experience [13,
20]. It is possible that the lack of dietary counselling, which
represented a key point of our previous studies, has con-
sistently contributed to a worse result. It is well known that
a multidisciplinary approach results in an improved meta-
bolic pattern, with positive influences on quality of life and
in better adherence. A recent, randomized study by Paes
Barreto shows that intensive dietary counselling in CKD
patients prescribed a LPD, determined a satisfactory level
of adherence (69 %) compared to patients with standard
counselling, in whom adherence averaged 48 %, quite
similar as in our study [15]. Most patients of Group 6-TD
(70 %), conversely, remained in the desired range of pro-
tein intake than in Group LPD, despite this difference was
at limit of statistical significance (p[ 0.05), likely due to
the limited power of our study to detect a true difference
between the groups. These data, however, clearly suggest
that the 6-TD, beyond its metabolic efficacy, is certainly
better accepted than the usual diet, probably for its sim-
plicity (no food to weight, large selection of meals) and for
its easiness to be memorized. Moreover, the relative sta-
bility of body weight observed in all the patients also
suggests that caloric intake was adequate in both groups.
We used 6 tips in our diet, since we considered them the
most important points to face when prescribing a diet.
Specific subsets of patients could have requested some
additional tips about a correct energy intake, like diabetic
patients, or the need to increase water ingestion and avoid
caffeine intake, like ADPKD patients. We did not consider
these points in 6-TD, however, assuming that these patients
had their diagnosis years before the onset of renal failure
and, therefore, were certainly aware of the peculiar prob-
lems linked to their condition. It seems useful, however, in
ADPKD patients, to stress these advices not considered in
the written diet.
Last, no difference was detected between the groups in
the other metabolic parameters, all maintained in a satis-
factory range according to our targets.
The major limit of the study resides in the small number
of patients enrolled in the protocol and the short follow-up
period that do not allow to evaluate patients outcomes.
Moreover, patients of both groups started the experimental
study in good clinical and metabolic conditions and there-
fore are not representative of the general CKD population,
although it seems reasonable that the beneficial effects of
6-TD on patients’ adherence and on metabolic profile may
be extended to all CKD patients. Another limit of the study
is that the 6-TD mostly reflects the dietary habits of
Southern Europe and, although it could be easily adapted to
Western people, cannot certainly be prescribed to Eastern
populations due to obvious differences in selection of
nutrients and in meals schedule. Last, no questionnaire was
performed throughout the study period to ascertain the
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quality of patients’ diets, the biologic level of proteins or the
daily amount of fruit/vegetables they really ingested.
In conclusion, the adoption of the 6-TD was character-
ized by a better metabolic pattern (decreased intake of
protein, decreased excretion of phosphate) and a higher
adherence rate than LPDs; in fact, the greater flexibility in
quantity and quality of food selection and the easiness in
realizing these tips encourage patients to follow the dietary
restriction.
However, despite these beneficial effects of 6-TD, we
continue to emphasize the need of dietitians and of a
continuous dietary counselling in clinical practice, mostly
when we must prescribe a ‘‘real’’ LPD (0.55–0.60 kg/day)
or a VLDP (0.3 g/kg/day) and we need a good adherence to
the dietary plan [27]. The 6-TD, therefore, may represent a
valid alternative to a standard low-protein diet, mostly
when a dietary counselling is not available.
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